Journal of Biomedical and Clinical Research 15(1): 74-78, doi: 10.2478/jbcr-2022-0010
A Retrospective Analysis of Treatment of Covid-19 with Favipiravir
expand article infoAigul M. Utegenova, Sholpan A. Kulzhanova, Maiya E. Konkayeva, Zauresh K. Smagulova, Nazira N. Beisenbieva, Gulnara T. Tuleshova
© Aigul Utegenova, Sholpan Kulzhanova, Maiya Konkayeva, Zauresh Smagulova, Nazira Beisenbieva, Gulnara Tuleshova.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits to copy and distribute the article for non-commercial purposes, provided that the article is not altered or modified and the original author and source are credited.
Citation: Utegenova AM, Kulzhanova SA, Konkayeva ME, Smagulova ZK, Beisenbieva NN, Tuleshova GT (2022) A Retrospective Analysis of Treatment of Covid-19 with Favipiravir. Journal of Biomedical and Clinical Research 15(1): 74-78. https://doi.org/10.2478/jbcr-2022-0010
Open Access
Abstract
One of the potential therapeutic agents for treating COVID-19 is favipiravir (FPV). This retrospective study compared the treatment of COVID-19 with (FVP group) or without (control group) favipiravir. Demographic characteristics and initial clinical indicators in the two groups were comparable. The level of oxygen saturation, respiratory rate, and prevalence of chest pain in the FVP group returned to normal significantly earlier (on the seventh day) compared to the control group (p<0.05). Improvement of patients’ condition in the FVP group occurred significantly earlier than in the control group (p <0.001). In conclusion, FVP treatment’s efficacy was higher than the control management strategy and established an individualized set of therapeutic agents. However, more detailed studies are needed to evaluate the efficacy of COVID-19 treatment with favipiravir fully.
Keywords
favipiravir, COVID-19, SARS-CoV-2, antiviral therapy, pandemic